This article was originally published in Pharmaceutical Approvals Monthly
Company submitted an NDA Oct. 1 for the Cytovene (ganciclovir) pro-drug for treatment of cytomegalovirus retinitis in patients with AIDS. Phase III study results showed that two groups of patients taking either valganciclovir or Cytovene had equivalent rates of progression of CMV retinitis as measured by retinal photograph
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.